Drug Shortage Report for TEVA-VENLAFAXINE XR
Report ID | 113803 |
Drug Identification Number | 02275023 |
Brand name | TEVA-VENLAFAXINE XR |
Common or Proper name | VENLAFAXINE XR 37.5MG CAP |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | VENLAFAXINE |
Strength(s) | 37.5MG |
Dosage form(s) | CAPSULE (EXTENDED RELEASE) |
Route of administration | ORAL ORAL |
Packaging size | 100 |
ATC code | N06AX |
ATC description | ANTIDEPRESSANTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-04-29 |
Estimated end date | Unknown |
Actual end date | 2020-06-08 |
Shortage status | Resolved |
Updated date | 2020-06-11 |
Company comments | Product is discontinued, and transitioned to the ACT product. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-05-01 | English | Compare |
v2 | 2020-05-01 | French | Compare |
v3 | 2020-06-11 | English | Compare |
v4 | 2020-06-11 | French | Compare |
Showing 1 to 4 of 4